IEMAD (modified MIME) therapy for refractory or relapsed non-Hodgkin's lymphoma.
- Author:
Hong-Hua LI
1
;
Xiao-Xiong WU
;
Quan-Shun WANG
;
Yu ZHAO
;
Jian BO
;
Shu-Hong WANG
;
Wan-Ming DA
;
Li YU
Author Information
1. Department of Hematology, General Hospital of PLA, Beijing 100853, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Antineoplastic Combined Chemotherapy Protocols;
administration & dosage;
therapeutic use;
Cytarabine;
administration & dosage;
Dexamethasone;
administration & dosage;
Drug Administration Schedule;
Etoposide;
administration & dosage;
Female;
Humans;
Ifosfamide;
administration & dosage;
Lymphoma, Non-Hodgkin;
drug therapy;
pathology;
Male;
Methotrexate;
administration & dosage;
Middle Aged;
Mitoguazone;
administration & dosage;
Recurrence
- From:
Journal of Experimental Hematology
2006;14(2):298-300
- CountryChina
- Language:Chinese
-
Abstract:
The study was aimed to evaluate the effect of IEMAD (modified MIME) composed of isofosfamide, VM26 or VP16, methotrexate, cytarabine, dexamethasone or methylprednisolone, in treatment of refractory or relapsed non-Hodgkin's lymphoma. Twenty-five patients with refractory or relapsed non-Hodgkin's lymphoma (11 refractory NHL patients, 14 relapsed NHL patients) were treated with IEMAD regimen. The results showed that the complete remission rate was 24.0% (6/25) and the partial remission rate was 28.0%, having an overall response rate of 52%. The median survival duration was 13 months and the median duration of progression-free survival was 8 months. The most frequent complications were gastrointestinal complaint (nausea, vomiting etc.) and myelosuppression. No treatment related mortality was found. It is concluded that the IEMAD (modified MIME) regimen may be a safe and effective regimen that can be used in treatment of patients with refractory or relapsed non-Hodgkin's lymphoma who did not respond to other regimens.
